Chemistry:Neboglamine
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Other names | Nebostinel; N-(4,4-Dimethylcyclohexyl)-L-α-glutamine |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C13H24N2O3 |
| Molar mass | 256.346 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Neboglamine (INN) (developmental code names CR-2249, XY-2401), formerly known as nebostinel, is a positive allosteric modulator of the glycine site of the NMDA receptor which is under investigation for Rottapharm for the treatment of schizophrenia and cocaine dependence.[1][2][3][4][5][6] It shows cognition- and memory-enhancing effects in animal models.[7][8][9] As of June 2015, it is in phase II clinical trials for both schizophrenia and cocaine abuse.[10]
See also
References
- ↑ "Antipsychotic-like effects of the N-methyl-D-aspartate receptor modulator neboglamine: an immunohistochemical and behavioural study in the rat". Pharmacological Research 61 (5): 430–6. May 2010. doi:10.1016/j.phrs.2009.12.010. PMID 20045056.
- ↑ "Glutamatergic transmission in schizophrenia: from basic research to clinical practice". Current Opinion in Psychiatry 25 (2): 96–102. March 2012. doi:10.1097/YCO.0b013e32835035b2. PMID 22297716.
- ↑ "Drug Development in Schizophrenia: Summary and Table". Pharmaceutical Medicine 28 (5): 265–271. 2014. doi:10.1007/s40290-014-0070-6. ISSN 1178-2595.
- ↑ "Novel NMDA receptor modulators: an update". Expert Opinion on Therapeutic Patents 22 (11): 1337–52. November 2012. doi:10.1517/13543776.2012.728587. PMID 23009122.
- ↑ "Glutamatergic agents for schizophrenia: current evidence and perspectives". Expert Review of Clinical Pharmacology 8 (3): 335–52. May 2015. doi:10.1586/17512433.2015.1040393. PMID 25916667.
- ↑ "Emerging drugs for schizophrenia: an update". Expert Opinion on Emerging Drugs 19 (4): 511–31. December 2014. doi:10.1517/14728214.2014.958148. PMID 25234340.
- ↑ "CR 2249: a new putative memory enhancer. Behavioural studies on learning and memory in rats and mice". The Journal of Pharmacy and Pharmacology 48 (12): 1290–7. December 1996. doi:10.1111/j.2042-7158.1996.tb03938.x. PMID 9004193.
- ↑ "Characterization of a novel putative cognition enhancer mediating facilitation of glycine effect on strychnine-resistant sites coupled to NMDA receptor complex". Neuropharmacology 36 (8): 1057–64. August 1997. doi:10.1016/S0028-3908(97)00092-0. PMID 9294970.
- ↑ "Cognition Enhancing Profile of CR 2249, a New NMDA-Glycine Site Modulator". CNS Drug Reviews 3 (3): 245–259. 1997. doi:10.1111/j.1527-3458.1997.tb00326.x. ISSN 1080-563X.
- ↑ "Neboglamine". AdisInsight. http://adisinsight.springer.com/drugs/800004810.
External links
 |  |
